Special Issue "Therapeutic Agents for Neurological Disorders"
Deadline for manuscript submissions: 31 December 2020.
Interests: neurodegenerative diseases, Alzheimer’s disease, dementia, cell biology, molecular biology, ageing
The World Health Organization defines neurological disorders as disabling conditions that encompass but are not limited to cerebrovascular diseases, epilepsy, dementias including Alzheimer’s, multiple sclerosis, movement disorders resulting from nervous system deficits, brain tumours, neuroinfections and neurological disorders as a result of malnutrition 1. Globally, in 2016, neurological disorders were the leading cause of disability-adjusted life years (DALYs) (276 million [95% UI 247–308]) and second leading cause of deaths (9.0 million [8.8–9.4]) 2. The absolute number of deaths and DALYs from all neurological disorders combined increased by 39% and 15% respectively2. These figures outline an impending epidemic that requires urgent attention.
Treatments for neurological disorders are challenging, but numerous advancements have been made in identifying mechanisms and delineating pathways underlying these diseases. Advances in technologies that garner information from the fields of bioinformatics and next generation and whole genome sequencing have added invaluable support in identifying ‘culprit’ genes and proteins. Using this information, scientists and clinicians have ventured into areas previously deemed ‘fiction.’ From brain-controlled, non-invasive muscle stimulators that help paraplegics walk to the editing of the CEP290 gene in individuals with Leber congenital amaurosis 10 (LCA10) and a plethora of therapies in between, biomedicine has made giant leaps in just over two decades.
In this Special Issue, we aim to draw together research from experts in the field that highlight therapeutic agents and strategies, and identify future directions that will lead to discoveries and therapies for neurological disorders.
Dr. Damian Holsinger
- GBD 2016 Neurology Collaborators (2019) Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 18: 459–80.
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- brain injury
- spinal cord injury
- neurodevelopmental disorders
- nerve repair
- brain tumors